Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy
Author(s) -
Julio A. Panza,
Alicia M. Ellis,
Hussein R. AlKhalidi,
Thomas A. Holly,
Daniel S. Berman,
Jae K. Oh,
Gerald M. Pohost,
George Sopko,
Łukasz Chrzanowski,
Daniel B. Mark,
Tomasz Kukulski,
Liliana Favaloro,
Gerald Maurer,
Pedro Sílvio Farsky,
Ru San Tan,
Federico M. Asch,
Eric J. Velazquez,
Jean L. Rouleau,
Kerry L. Lee,
Robert O. Bonow
Publication year - 2019
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1807365
Subject(s) - medicine , ejection fraction , cardiology , hazard ratio , ischemic cardiomyopathy , coronary artery disease , revascularization , dobutamine , cardiomyopathy , myocardial infarction , heart failure , confidence interval , hemodynamics
The role of assessment of myocardial viability in identifying patients with ischemic cardiomyopathy who might benefit from surgical revascularization remains controversial. Furthermore, although improvement in left ventricular function is one of the goals of revascularization, its relationship to subsequent outcomes is unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom